Tevogen Bio Holdings Inc. financial data

Symbol
TVGN, TVGNW on Nasdaq
Location
15 Independence Boulevard, Suite 410, Warren, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30.4 % +366%
Debt-to-equity -154 % -123%
Return On Equity 415 % +3373%
Return On Assets -775 % -1160%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 197M shares +18.4%
Common Stock, Shares, Outstanding 194M shares +14.7%
Entity Public Float 21.4M USD -15.9%
Common Stock, Value, Issued 19.4K USD +14.7%
Weighted Average Number of Shares Outstanding, Basic 184M shares +19.6%
Weighted Average Number of Shares Outstanding, Diluted 184M shares +19.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12M USD -55.5%
General and Administrative Expense 19.3M USD +24.3%
Costs and Expenses 29.5M USD +884%
Operating Income (Loss) -31.2M USD +26.4%
Nonoperating Income (Expense) 2.21M USD -58.8%
Net Income (Loss) Attributable to Parent -31.2M USD -426%
Earnings Per Share, Basic 0 USD/shares +89.3%
Earnings Per Share, Diluted 0 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD
Assets, Current 2.06M USD -15.8%
Property, Plant and Equipment, Net 164K USD -56.4%
Operating Lease, Right-of-Use Asset 1.48M USD +319%
Other Assets, Noncurrent 566K USD +325%
Assets 4.27M USD +29%
Accounts Payable, Current 4.24M USD -36.4%
Accrued Liabilities, Current 1.61M USD -9.19%
Liabilities, Current 8.08M USD -23.8%
Operating Lease, Liability, Noncurrent 1.18M USD +1116%
Liabilities 13.8M USD +25.7%
Retained Earnings (Accumulated Deficit) -129M USD -31.8%
Stockholders' Equity Attributable to Parent -9.48M USD -24.2%
Liabilities and Equity 4.27M USD +29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.31M USD -52.9%
Net Cash Provided by (Used in) Financing Activities 4M USD +64.7%
Net Cash Provided by (Used in) Investing Activities -133K USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 194M shares +14.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 692K USD +161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 685K USD -39.6%
Deferred Tax Assets, Valuation Allowance 16.6M USD +123%
Deferred Tax Assets, Gross 16.6M USD +120%
Operating Lease, Liability 235K USD
Depreciation 40.6K USD +0%
Payments to Acquire Property, Plant, and Equipment 133K USD
Lessee, Operating Lease, Liability, to be Paid 244K USD
Property, Plant and Equipment, Gross 722K USD 0%
Operating Lease, Liability, Current 328K USD +22%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 230K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.59K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.81M USD +81.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 111M USD +26.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 59.7K USD -51.4%
Share-based Payment Arrangement, Expense 20.8M USD -21.8%
Interest Expense 24.6K USD -84.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%